Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 - Malta

SAFETY DATA SHEET



AQUAOIL 2775-36 - All variants

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1 Product identifier Product name

: AQUAOIL 2775-36 - All variants

1.2 Relevant identified uses of the substance or mixture and uses advised againstProduct use: Paint.

1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

e-mail address of person : Prod-safe@teknos.com

responsible for this SDS

National contact

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

1.4 Emergency telephone number

National advisory body/Poison Centre

 Telephone number
 : Malta Competition and Consumer Affairs Authority (MCCAA): +356 2395 2000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Skin Sens. 1, H317

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements

Hazard pictograms



Signal word Hazard statements <u>Precautionary statements</u>	Warning H317 - May cause an allergic skin reaction.	
Prevention	P280 - Wear protective gloves. P261 - Avoid breathing vapour.	
Response	 P362 + P364 - Take off contaminated clothing and wash it before reuse. P302 + P352 - IF ON SKIN: Wash with plenty of water. P333 + P313 - If skin irritation or rash occurs: Get medical advice or attention. 	
Storage	Not applicable.	
Disposal	 P501 - Dispose of contents and container in accordance with all local, regional national and international regulations. 	Ι,
Hazardous ingredients	 Contains: EO bis(benztriazolyl)phenylpropionat; Cobalt bis(2-ethylhexanoate); 1,2-benzisothiazol-3(2H)-one and 2-methyl-2H-isothiazol-3-one 	

SECTION 2: Hazards identification

not result in classification

Supplemental label elements	:	Contains biocidal products for dry film and in-can preservation: IPBC and Bronopol and BIT and MIT and OIT and C(M)IT/MIT (3:1) and DTBMA and MBIT. Risk of skin sensitisation.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	
2.3 Other hazards		
Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII	:	This mixture does not contain any substances that are assessed to be a PBT or a vPvB.
Other hazards which do	:	None known.

SECTION 3: Composition/information on ingredients

Identifiers	%	Classification	Specific Conc. Limits, M-factors and ATEs	Туре
REACH #: 01-2119475108-36 EC: 203-905-0 CAS: 111-76-2 Index: 603-014-00-0	≤3	Acute Tox. 4, H302 Acute Tox. 3, H331 Skin Irrit. 2, H315 Eye Irrit. 2, H319	ATE [Oral] = 1200 mg/kg ATE [Inhalation (vapours)] = 3 mg/l	[1] [2]
REACH #: 01-2119475527-28 EC: 225-878-4 CAS: 5131-66-8 Index: 603-052-00-8	≤3	Skin Irrit. 2, H315 Eye Irrit. 2, H319	-	[1]
REACH #: 01-0000015075-76 EC: 400-830-7 CAS: 104810-48-2 Index: 607-176-00-3	<1	Skin Sens. 1A, H317 Aquatic Chronic 2, H411	-	[1]
EC: 259-627-5 CAS: 55406-53-6 Index: 616-212-00-7	<0.1	Acute Tox. 4, H302 Acute Tox. 3, H331 Eye Dam. 1, H318 Skin Sens. 1, H317 STOT RE 1, H372 (larynx) Aquatic Acute 1, H400 Aquatic Chronic 1, H410	ATE [Oral] = 400 mg/kg ATE [Inhalation (dusts and mists)] = 0.67 mg/l M [Acute] = 10 M [Chronic] = 1	[1]
REACH #: 01-2119524678-29 EC: 205-250-6 CAS: 136-52-7	<0.1	Eye Irrit. 2, H319 Skin Sens. 1A, H317 Repr. 1B, H360FD Aquatic Acute 1, H400 Aquatic Chronic 3, H412	M [Acute] = 1	[1]
EC: 200-143-0 CAS: 52-51-7 Index: 603-085-00-8	≤0.1	Acute Tox. 4, H302 Acute Tox. 4, H312 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT SE 3, H335	ATE [Oral] = 307 mg/kg ATE [Dermal] = 1100 mg/kg M [Acute] = 10	[1]
	Identifiers REACH #: 01-2119475108-36 EC: 203-905-0 CAS: 111-76-2 Index: 603-014-00-0 REACH #: 01-2119475527-28 EC: 225-878-4 CAS: 5131-66-8 Index: 603-052-00-8 REACH #: 01-0000015075-76 EC: 400-830-7 CAS: 104810-48-2 Index: 607-176-00-3 EC: 259-627-5 CAS: 55406-53-6 Index: 616-212-00-7 REACH #: 01-2119524678-29 EC: 205-250-6 CAS: 136-52-7 EC: 200-143-0 CAS: 52-51-7	REACH #: ≤3 01-2119475108-36 EC: EC: 203-905-0 CAS: 111-76-2 Index: 603-014-00-0 REACH #: 01-2119475527-28 EC: EC: 225-878-4 CAS: 5131-66-8 Index: 603-052-00-8 REACH #: Note: 603-052-00-8 <1	Identifiers % Classification REACH #: 01-2119475108-36 EC: 203-905-0 CAS: 111-76-2 Index: 603-014-00-0 ≤3 Acute Tox. 4, H302 Acute Tox. 3, H331 Skin Irrit. 2, H315 Eye Irrit. 2, H315 Eye Irrit. 2, H319 REACH #: 01-2119475527-28 EC: 225-878-4 CAS: 5131-66-8 Index: 603-052-00-8 ≤3 Skin Irrit. 2, H315 Eye Irrit. 2, H319 REACH #: 01-000015075-76 EC: 400-830-7 CAS: 104810-48-2 Index: 607-176-00-3 <1	Identifiers % Classification Specific Conc. Limits, M-factors and ATEs REACH #: 01-2119475108-36 EC: 203-905-0 CAS: 111-76-2 Index: 603-014-00-0 ≤3 Acute Tox. 4, H302 Acute Tox. 3, H331 Skin Irrit. 2, H315 Eye Irrit. 2, H315 Eye Irrit. 2, H319 ATE [Oral] = 1200 mg/kg REACH #: 01-2119475527-28 EC: 225-878-4 CAS: 5131-66-8 Index: 603-052-00-8 ≤3 Skin Irrit. 2, H315 Eye Irrit. 2, H319 - REACH #: 01-0000015075-76 EC: 400-830-7 CAS: 104810-48-2 Index: 607-176-00-3 ≤1 Skin Sens. 1A, H317 Aquatic Chronic 2, H411 - CAS: 5131-66-8 Index: 607-176-00-3 <0.1

SECTION 3: Composition/information on ingredients							
•			Aquatic Acute 1, H400				
1,2-benzisothiazol-3(2H)- one	EC: 220-120-9 CAS: 2634-33-5 Index: 613-088-00-6	<0.05	Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 Skin Sens. 1, H317 Aquatic Acute 1, H400	ATE [Oral] = 1020 mg/kg Skin Sens. 1, H317: C ≥ 0.05% M [Acute] = 1	[1]		
2-methyl-2H-isothiazol- 3-one	EC: 220-239-6 CAS: 2682-20-4	<0.01	Acute Tox. 3, H301 Acute Tox. 3, H311 Acute Tox. 2, H330 Skin Corr. 1B, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 EUH071	ATE [Oral] = 100 mg/kg ATE [Dermal] = 300 mg/kg ATE [Inhalation (dusts and mists)] = 0.11 mg/l Skin Sens. 1, H317: C $\geq 0.0015\%$ M [Acute] = 10 M [Chronic] = 1	[1]		
2-Octyl-2H-isothiazol-3-one	EC: 247-761-7 CAS: 26530-20-1 Index: 613-112-00-5	<0.0025	Acute Tox. 3, H301 Acute Tox. 3, H311 Acute Tox. 2, H330 Skin Corr. 1, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 EUH071	ATE [Oral] = 125 mg/kg ATE [Dermal] = 311 mg/kg ATE [Inhalation (dusts and mists)] = 0.27 mg/l Skin Sens. 1, H317: C $\geq 0.0015\%$ M [Acute] = 100 M [Chronic] = 100	[1]		
reaction mass of: 5-chloro- 2-methyl-4-isothiazolin- 3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol- 3-one [EC no. 220-239-6] (3:1)	CAS: 55965-84-9 Index: 613-167-00-5	<0.001	Acute Tox. 3, H301 Acute Tox. 2, H310 Acute Tox. 2, H330 Skin Corr. 1C, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 EUH071	ATE [Oral] = 53 mg/ kg ATE [Dermal] = 50 mg/kg ATE [Inhalation (vapours)] = 0.5 mg/l Skin Corr. 1C, H314: $C \ge 0.6\%$ Eye Dam. 1, H318: $C \ge 0.6\%$ Eye Irrit. 2, H319: $0.06\% \le C < 0.6\%$ Skin Sens. 1, H317: $C \ge 0.0015\%$ M [Acute] = 100 M [Chronic] = 100	[1]		
			See Section 16 for the full text of the H statements declared above.				

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section. <u>Type</u>

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

Occupational exposure limits, if available, are listed in Section 8.

: 12/10/2022

SECTION 4: First aid measures

	-					
4.1 Description of first aid measures						
Eye contact	:	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention if irritation occurs.				
Inhalation	:	Remove victim to fresh air and keep at rest in a position comfortable for breathing. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention if adverse health effects persist or are severe. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.				
Skin contact	:	Wash with plenty of soap and water. Remove contaminated clothing and shoes. Wash contaminated clothing thoroughly with water before removing it, or wear gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the event of any complaints or symptoms, avoid further exposure. Wash clothing before reuse. Clean shoes thoroughly before reuse.				
Ingestion	:	Wash out mouth with water. Remove dentures if any. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention if adverse health effects persist or are severe. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband.				
Protection of first-aiders	:	No action shall be taken involving any personal risk or without suitable training. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing thoroughly with water before removing it, or wear gloves.				

4.2 Most important symptoms and effects, both acute and delayed

Over-exposure signs/symptoms

Eye contact	: No specific data.
Inhalation	: No specific data.
Skin contact	: Adverse symptoms may include the following: irritation redness
Ingestion	: No specific data.
4.3 Indication of any in	nmediate medical attention and special treatment needed

Notes to physician	 Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
Specific treatments	: No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media Suitable extinguishing media	: Use an extinguishing agent suitable for the surrounding fire.
Unsuitable extinguishing media	: None known.

5.2 Special hazards arising from the substance or mixture

Hazards from the : In a fire or if heated, a pressure increase will occur and the container may burst. **substance or mixture**

: 24/10/2023 Date of previous issue

: 12/10/2022

SECTION 5: Firefighting measures			
Hazardous combustion products	: Decomposition products may include the following materials: carbon dioxide carbon monoxide metal oxide/oxides		
5.3 Advice for firefighters			
Special protective actions for fire-fighters	: Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.		
Special protective equipment for fire-fighters	: Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.		

SECTION 6: Accidental release measures

6.1 Personal precautions, pro	ote	ctive equipment and emergency procedures
For non-emergency personnel	:	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Avoid breathing vapour or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
For emergency responders	:	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	:	Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
6.3 Methods and material for	со	ntainment and cleaning up
Small spill	:	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	:	Stop leak if without risk. Move containers from spill area. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product.

6.4 Reference to other sections See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Do not get in eyes or on skin or clothing. Do not ingest. Avoid breathing vapour or mist. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Empty containers retain product residue and can be hazardous. Do not reuse container.
---------------------	--

SECTION 7: Handling and storage

Advice on general	
occupational hygiene	

: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.

7.3 Specific end use(s)

Recommendations	: Not available.
Industrial sector specific	: Not available.

Industria solutions

SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

Occupational exposure limits

Product/ingredient name	Exposure limit values		
Z-Butoxyethanol	EU OEL (Europe, 1/2022). Absorbed through skin. Notes: list of indicative occupational exposure limit values TWA: 20 ppm 8 hours. TWA: 98 mg/m ³ 8 hours. STEL: 50 ppm 15 minutes. STEL: 246 mg/m ³ 15 minutes.		

Biological exposure indices

Product/ingredient name		Exposure indices	
No exposure indices known.			
Recommended monitoring procedures	European Stand assessment of e values and mea atmospheres - (of exposure to c (Workplace atm for the measure	Id be made to monitoring standards, such as the following: dard EN 689 (Workplace atmospheres - Guidance for the exposure by inhalation to chemical agents for comparison with limit surement strategy) European Standard EN 14042 (Workplace Guide for the application and use of procedures for the assessment chemical and biological agents) European Standard EN 482 nospheres - General requirements for the performance of procedures ment of chemical agents) Reference to national guidance nethods for the determination of hazardous substances will also be	

DNELs/DMELs

Product/ingredient name	Туре	Exposure	Value	Populatio	n Effects
2-Butoxyethanol	DNEL	Long term Oral	6.3 mg/kg bw/day	General population	Systemic
	DNEL	Short term Oral	26.7 mg/ kg bw/day	General population	Systemic
	DNEL	Long term Inhalation	59 mg/m ³	General population	Systemic
	DNEL	Long term Inhalation	98 mg/m³	Workers	Systemic
	DNEL	Short term Inhalation	147 mg/m³	General population	Local
	DNEL	Short term	246 mg/m ³	Workers	Local
te of issue/Date of revision : 2	4/10/2023	Date of previous issue	: 12/10/2	022	Version : 1.01 6/18
QUAOIL 2775-36 - All variants				L	_abel No : <mark>5</mark> 2050

3-Butoxypropan-2-ol 3-botoxypropan-2-ol 3-iodo-2-propynyl-butyl carbamate 3-iodo-2-propynyl-butyl carbamate 3-iodo-2-	aort term nalation nort term nalation ng term nalation ng term Oral ng term Dermal ng term nalation nort term Dermal ng term nalation nort term nalation nort term nalation nort term nalation nort term nalation nort term	426 mg/m ³ 1091 mg/ m ³ 147 mg/m ³ 12.5 mg/ kg bw/day 22 mg/kg bw/day 43 mg/m ³ 52 mg/kg bw/day 50 % 50 % 50 % 50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³ 1.16 mg/m ³	General population Workers Workers General population General population Workers General population General population General population General population Workers Workers Workers	Systemic Systemic Systemic Systemic Systemic Systemic Local Local Local Local Systemic
3-Butoxypropan-2-ol 3-Butoxyp	ort term nalation ng term nalation ng term Oral ng term Dermal ng term nalation nort term nalation nort term nalation nort term nalation nort term nalation nort term nalation nort term	m ³ 147 mg/m ³ 12.5 mg/ kg bw/day 22 mg/kg bw/day 43 mg/m ³ 52 mg/kg bw/day 50 % 50 % 50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	Workers Workers General population General population Workers General population General population General population Workers Workers Workers	Systemic Systemic Systemic Systemic Local Local Local Local
3-Butoxypropan-2-ol DNEL Investion DNEL DNEL DNEL DNEL DNEL Investion DNEL <td< td=""><td>nalation ng term nalation ng term Oral ng term Dermal ng term nalation nort term nalation nort term nalation nort term nalation nort term nalation nort term nalation nort term</td><td>m³ 147 mg/m³ 12.5 mg/ kg bw/day 22 mg/kg bw/day 43 mg/m³ 52 mg/kg bw/day 50 % 50 % 50 % 50 % 0.023 mg/ m³ 0.07 mg/m³</td><td>Workers General population General population Workers General population General population Workers Workers Workers</td><td>Systemic Systemic Systemic Systemic Local Local Local Local</td></td<>	nalation ng term nalation ng term Oral ng term Dermal ng term nalation nort term nalation nort term nalation nort term nalation nort term nalation nort term nalation nort term	m ³ 147 mg/m ³ 12.5 mg/ kg bw/day 22 mg/kg bw/day 43 mg/m ³ 52 mg/kg bw/day 50 % 50 % 50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	Workers General population General population Workers General population General population Workers Workers Workers	Systemic Systemic Systemic Systemic Local Local Local Local
3-Butoxypropan-2-ol Butoxyprop	ng term nalation ng term Oral ng term Dermal ng term nalation nort term nalation nort term nalation nort term nalation nort term nalation nort term	147 mg/m ³ 12.5 mg/ kg bw/day 22 mg/kg bw/day 43 mg/m ³ 52 mg/kg bw/day 50 % 50 % 50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	General population General population General population General population General population Workers Workers Workers	Systemic Systemic Systemic Systemic Local Local Local Local
Number Internation Internation DNEL DNEL DNEL DNEL DNEL DNEL <td>nalation ng term Oral ng term Dermal ng term nalation nort term nalation nort term nalation nort term nalation nort term nalation nort term</td> <td>12.5 mg/ kg bw/day 22 mg/kg bw/day 43 mg/m³ 52 mg/kg bw/day 50 % 50 % 50 % 50 % 0.023 mg/ m³ 0.07 mg/m³</td> <td>General population General population General population General population General population Workers Workers Workers</td> <td>Systemic Systemic Systemic Systemic Local Local Local Local</td>	nalation ng term Oral ng term Dermal ng term nalation nort term nalation nort term nalation nort term nalation nort term nalation nort term	12.5 mg/ kg bw/day 22 mg/kg bw/day 43 mg/m ³ 52 mg/kg bw/day 50 % 50 % 50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	General population General population General population General population General population Workers Workers Workers	Systemic Systemic Systemic Systemic Local Local Local Local
DNEL Loi DNEL DNEL DNEL	ng term Oral ng term Dermal ng term nalation ng term Dermal nort term Dermal ng term Dermal ng term Dermal ng term Dermal ng term nalation nort term nalation nort term nalation nort term nalation nort term nalation nort term	kg bw/day 22 mg/kg bw/day 43 mg/m ³ 52 mg/kg bw/day 50 % 50 % 50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	population General population General population Workers General population Workers Workers Workers	Systemic Systemic Systemic Local Local Local Local
Image: Second	ng term Dermal ng term nalation ng term Dermal nort term Dermal ng term Dermal ng term Dermal ng term Dermal ng term nalation nort term nalation nort term nalation nort term nalation nort term	kg bw/day 22 mg/kg bw/day 43 mg/m ³ 52 mg/kg bw/day 50 % 50 % 50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	population General population General population Workers General population Workers Workers Workers	Systemic Systemic Systemic Local Local Local Local
Image: Second	ng term Dermal ng term nalation ng term Dermal nort term Dermal ng term Dermal ng term Dermal ng term Dermal ng term nalation nort term nalation nort term nalation nort term nalation nort term	kg bw/day 22 mg/kg bw/day 43 mg/m ³ 52 mg/kg bw/day 50 % 50 % 50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	General population General population Workers General population General population Workers Workers Workers	Systemic Systemic Systemic Local Local Local Local
S-iodo-2-propynyl-butyl carbanate B-iodo-2-propynyl-butyl carbanate B-iodo-2-propyny	ng term nalation ng term Dermal nort term Dermal ng term Dermal ng term Dermal ng term nalation nort term nalation nort term nalation nort term nalation nort term nalation nort term	22 mg/kg bw/day 43 mg/m ³ 52 mg/kg bw/day 50 % 50 % 50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	General population General population Workers General population General population Workers Workers Workers	Systemic Systemic Local Local Local Local
S-iodo-2-propynyl-butyl carbanate B-iodo-2-propynyl-butyl carbanate B-iodo-2-propyny	ng term nalation ng term Dermal nort term Dermal ng term Dermal ng term Dermal ng term nalation nort term nalation nort term nalation nort term nalation nort term nalation nort term	bw/day 43 mg/m ³ 52 mg/kg bw/day 50 % 50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	population General population Workers General population Workers Workers Workers	Systemic Systemic Local Local Local Local
A-iodo-2-propynyl-butyl carbamate B-iodo-2-propynyl-butyl carbamate B-iodo-2-propyny	nalation ng term Dermal nort term Dermal ng term Dermal ng term Dermal ng term nalation nort term nalation nort term nalation nort term nalation nort term nalation nort term	43 mg/m ³ 52 mg/kg bw/day 50 % 50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	General population Workers General population General population Workers Workers Workers	Systemic Local Local Local Local Local
A-iodo-2-propynyl-butyl carbamate B-iodo-2-propynyl-butyl carbamate B-iodo-2-propyny	nalation ng term Dermal nort term Dermal ng term Dermal ng term Dermal ng term nalation nort term nalation nort term nalation nort term nalation nort term nalation nort term	52 mg/kg bw/day 50 % 50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	population Workers General population General population Workers Workers Workers	Systemic Local Local Local Local Local
S-iodo-2-propynyl-butyl carbamate B-iodo-2-propynyl-butyl carbamate B-iodo-2-propynyl-butyl carbamate B-iodo-2-propynyl-butyl carbamate B-iodo-2-propynyl-butyl carbamate B-iodo-2-propynyl-butyl carbamate DNEL	ng term Dermal nort term Dermal ng term Dermal ng term Dermal ng term nalation nort term nalation nort term nalation nort term nalation nort term nalation nort term	bw/day 50 % 50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	Workers General population General population Workers Workers Workers	Local Local Local Local Local
s-iodo-2-propynyl-butyl carbamate b-iodo-2-propynyl-butyl carbamate b-iodo-2-propynyl-butyl carbamate b-iodo DNEL D	nort term Dermal ng term Dermal ng term Dermal ng term Dermal ng term nalation nort term nalation nort term nalation nort term nalation ng term	bw/day 50 % 50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	General population General population Workers Workers Workers	Local Local Local Local Local
A-iodo-2-propynyl-butyl carbamater A-boxet A-b	ng term Dermal nort term Dermal ng term Dermal ng term nalation nort term nalation nort term nalation ng term	50 % 50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	population General population Workers Workers Workers	Local Local Local
A-iodo-2-propynyl-butyl carbamater A-boxet A-b	ng term Dermal nort term Dermal ng term Dermal ng term nalation nort term nalation nort term nalation ng term	50 % 50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	population General population Workers Workers Workers	Local Local Local
B-iodo-2-propynyl-butyl carbamate DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL	nort term Dermal ng term Dermal ng term nalation nort term nalation nort term nalation nalation ng term	50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	General population Workers Workers Workers	Local Local
e-iodo-2-propynyl-butyl carbamate b-iodo-2-propynyl-butyl carbamate Cobalt bis(2-ethylhexanoate) Cobalt bis(2-ethylhex	nort term Dermal ng term Dermal ng term nalation nort term nalation nort term nalation ng term	50 % 50 % 0.023 mg/ m ³ 0.07 mg/m ³	population Workers Workers Workers	Local Local
B-iodo-2-propynyl-butyl carbamate DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL	ng term Dermal ng term nalation ort term nalation nort term nalation ng term	50 % 0.023 mg/ m ³ 0.07 mg/m ³	Workers Workers Workers	Local
B-iodo-2-propynyl-butyl carbamate DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL	ng term Dermal ng term nalation ort term nalation nort term nalation ng term	50 % 0.023 mg/ m ³ 0.07 mg/m ³	Workers Workers	Local
S-iodo-2-propynyl-butyl carbamate DNEL Lou DNEL Shi DNEL Lou DNEL Shi DNEL	ng term nalation ort term nalation nort term nalation ng term	0.023 mg/ m³ 0.07 mg/m³	Workers	
Cobalt bis(2-ethylhexanoate) Cobalt bis(2-ethylhexanoate) Cobalt bis(2-ethylhexanoate) DNEL Lou DNEL Lou DNEL Lou DNEL Lou DNEL Lou DNEL Lou DNEL Lou DNEL Lou DNEL Lou DNEL Sh DNEL Sh	nalation fort term nalation fort term nalation ng term	m ³ 0.07 mg/m ³		Systemic
Cobalt bis(2-ethylhexanoate) Cobalt bis(2-ethylhexanoate) Cobalt bis(2-ethylhexanoate) Cobalt bis(2-ethylhexanoate) DNEL D	oort term nalation nort term nalation ng term	0.07 mg/m³	Workers	1
Cobalt bis(2-ethylhexanoate) Cobalt bis(2-ethylhexanoate) Cobalt bis(2-ethylhexanoate) DNEL	nalation lort term nalation ng term	-	Workers	
DNELSh DNELDNELDNELDNELDNELDNELDNELDNELDNELDNELDNELDNELDNELDNELDNELDNELSh <t< td=""><td>ort term nalation ng term</td><td>1.16 mg/m³</td><td></td><td>Systemic</td></t<>	ort term nalation ng term	1.16 mg/m³		Systemic
Cobalt bis(2-ethylhexanoate) Cobalt bis(2-ethylhexanoate) DNEL	nalation ng term	1.16 mg/m ³		
DNELLorCobalt bis(2-ethylhexanoate)DNELLorDNELDNELLorDNELDNELShDNELShDNEL	ng term	-	Workers	Local
Cobalt bis(2-ethylhexanoate) DNEL Lon DNEL DNEL DNEL Lon DNEL Lon DNEL Lon DNEL Lon DNEL Sh DNEL Sh	-			
Cobalt bis(2-ethylhexanoate) DNEL Lon DNEL Lon DNEL Lon DNEL Lon DNEL Lon DNEL Lon DNEL Sh DNEL Sh	-	1.16 mg/m ³	Workers	Local
DNELLorCobalt bis(2-ethylhexanoate)DNELLorDNELDNELDNELBronopolDNELLorDNELDNELShDNELShDNELDNELShDNELDNELShDNEL<		Ŭ		
Cobalt bis(2-ethylhexanoate) DNEL Lon DNEL DNEL DNEL Bronopol DNEL Lon DNEL DNEL Sh DNEL Sh DNEL	ng term Dermal	2 mg/kg	Workers	Systemic
Bronopol Bro		bw/day		-)
Bronopol Bro	ng term	37 µg/m³	General	Local
Bronopol DNEL Lor Bronopol DNEL Lor DNEL DNEL DNEL DNEL DNEL DNEL Sh DNEL DNEL DNEL DNEL DNEL DNEL DNEL DNEL	nalation	07 µg/m	population	Loodi
Bronopol Bronopol Bronopol Bronopol Bronopol BroneL	ng term Oral	175 µg/kg	General	Systemic
Bronopol DNEL Inh DNEL Lou DNEL Sh DNEL Sh	ng term Orai		-	Systemic
Bronopol DNEL Inh DNEL Lou DNEL Sh DNEL Sh		bw/day	population	1 1
Bronopol DNEL Shi DNEL Loi DNEL Shi DNEL DNEL DNEL Shi DNEL Shi DNEL Shi DNEL Shi DNEL Shi DNEL DNEL DNEL DNEL DNEL Shi DNEL DNEL DNEL Shi DNEL Shi	ng term	235.1 µg/	Workers	Local
. DNEL Loi DNEL DNEL Shi DNEL Shi Shi Shi Shi Shi Shi<	nalation	m ³	0	Lesel
DNEL Shuber Shub	ort term Dermal	4 µg/cm²	General	Local
DNEL Shuber Shub		4	population	1 1
DNEL Loi DNEL Shi DNEL Shi DNEL Shi DNEL Loi DNEL Loi DNEL Shi DNEL Shi DNEL Shi DNEL Shi DNEL Shi DNEL Shi	ng term Dermal	4 µg/cm²	General	Local
DNEL Loi DNEL Shi DNEL Shi DNEL Shi DNEL Loi DNEL Loi DNEL Shi DNEL Shi DNEL Shi DNEL Shi DNEL Shi DNEL Shi			population	
DNEL Loi DNEL Shi DNEL Shi DNEL Loi DNEL Loi DNEL DNEL DNEL Shi DNEL Shi DNEL Shi DNEL Shi DNEL Shi	ort term Dermal	8 µg/cm ²	Workers	Local
DNEL Sh DNEL Sh DNEL Loi DNEL DNEL DNEL Sh DNEL Sh DNEL Sh DNEL Sh	ng term Dermal	8 µg/cm²	Workers	Local
DNEL Sh DNEL Loi DNEL Loi DNEL Sh DNEL Sh DNEL Sh DNEL Sh	ng term Oral	0.18 mg/	General	Systemic
DNEL Sh DNEL Loi DNEL Loi DNEL Sh DNEL Sh DNEL Sh DNEL Sh		kg bw/day	population	
DNEL Inh DNEL Loi DNEL Sh DNEL DNEL Loi DNEL Sh	ort term Oral	0.5 mg/kg	General	Systemic
DNEL Inh DNEL Loi DNEL Sh DNEL DNEL DNEL Sh		bw/day	population	
DNEL Loi Inh DNEL Sh DNEL Loi DNEL Loi DNEL Sh	ort term	0.6 mg/m ³	General	Local
DNEL Inh DNEL Sh Inh DNEL Loi DNEL Sh	nalation	-	population	
DNEL Inh DNEL Sh Inh DNEL Loi DNEL Sh	ng term	0.6 mg/m ³	General	Systemic
DNEL Sh Inh DNEL Loi DNEL Sh	nalation	-	population	-
DNEL Sh Inh DNEL Loi DNEL Sh	ng term Dermal	0.7 mg/kg	General	Systemic
DNEL Inh DNEL DNEL Sh	-	bw/day	population	
DNEL Inh DNEL DNEL Sh	ort term	1.8 mg/m ³	General	Systemic
DNEL Loi DNEL Sh	nalation	J	population	
DNEL Sh	ng term Dermal	2 mg/kg	Workers	Systemic
	J	bw/day		,
	ort term Dermal	2.1 mg/kg	General	Systemic
		bw/day	population	
	ort term	2.5 mg/m ³	Workers	Local
		2.5 mg/m	**017619	LUCAI
		25 mg/m3	Morkora	
	nalation	2.5 mg/m ³	Workers	Local
	ng term	0.5		Question
	ng term nalation	3.5 mg/m ³	Workers	Systemic
Inh	ng term nalation ng term			
of issue/Date of revision : 24/10/2023 Date	ng term nalation	I I)22	Version : 1.01 7/1

	DNEL	Short term Dermal	6 mg/kg	Workers	Systemic
			bw/day		
	DNEL	Short term	10.5 mg/m ³	Workers	Systemic
		Inhalation			
1,2-benzisothiazol-3(2H)-one	DNEL	Long term Dermal	0.345 mg/	General	Systemic
			kg bw/day	population	
	DNEL	Long term Dermal	0.966 mg/ kg bw/day	Workers	Systemic
	DNEL	Long term	1.2 mg/m ³	General	Systemic
		Inhalation		population	
	DNEL	Long term	6.81 mg/m ³	Workers	Systemic
		Inhalation			
2-methyl-2H-isothiazol-3-one	DNEL	Long term	0.021 mg/	General	Local
		Inhalation	m³	population	
	DNEL	Long term	0.021 mg/	Workers	Local
		Inhalation	m ³		
	DNEL	Long term Oral	0.027 mg/	General	Systemic
			kg bw/day	population	
	DNEL	Short term	0.043 mg/	General	Local
		Inhalation	m ³	population	1 1
	DNEL	Short term Inhalation	0.043 mg/ m³	Workers	Local
	DNEL	Short term Oral	0.053 mg/	General	Systemic
			kg bw/day	population	
reaction mass of: 5-chloro-2-methyl-	DNEL	Long term	0.02 mg/m ³	General	Local
4-isothiazolin-3-one [EC no. 247-500-7] and 2-methyl-2H- isothiazol-3-one [EC no. 220-239-6]		Inhalation		population	
(3:1)					
	DNEL	Long term Inhalation	0.02 mg/m ³	Workers	Local
	DNEL	Short term	0.04 mg/m ³	General	Local
		Inhalation		population	
	DNEL	Short term	0.04 mg/m ³	Workers	Local
		Inhalation			
	DNEL	Long term Oral	0.09 mg/	General	Systemic
			kg bw/day	population	-
	DNEL	Short term Oral	0.11 mg/	General	Systemic
			kg bw/day	population	-

PNECs

No PNECs available

8.2 Exposure controls

0.2 Exposure controls		
Appropriate engineering controls	:	Good general ventilation should be sufficient to control worker exposure to airborne contaminants.
Individual protection measu	ires	
Hygiene measures	:	Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Contaminated work clothing should not be allowed out of the workplace. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.
Eye/face protection	:	Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.
Skin protection		

SECTION 8: Exposure controls/personal protection

Hand protection	: Chemical-resistant, impervious gloves complying with an approved standard shou be worn at all times when handling chemical products if a risk assessment indicat this is necessary. Considering the parameters specified by the glove manufactur check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.	tes
	Recommendations : Wear suitable gloves tested to EN374.	
	> 8 hours (breakthrough time): Nitrile gloves. thickness > 0.3 mm	
	Not recommended polyvinyl alcohol (PVA) gloves	
Body protection	: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.	ć
Other skin protection	: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.	•
Respiratory protection	: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other importa aspects of use.	
	Filter type (spray application): A P	
Environmental exposure controls	: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the proces equipment will be necessary to reduce emissions to acceptable levels.	

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

<u>Appearance</u>	
Physical state	: Liquid.
Colour	: Colourless.
Odour	: Slight
Odour threshold	: Not available.
Melting point/freezing point	: Not available.
Initial boiling point and boiling range	÷

Ingredient name		°C	°F	Method
water		100	212	
2-Butoxyethanol		171 to 171.5	339.8 to 340.7	IP 123-93
Flammability	: Not ava	ilable.		
Lower and upper explosion limit		Not applicable. Not applicable.		
Flash point	: Closed	cup: >100°C (>212	2°F)	
Auto-ignition temperature	:			
Ingredient name		°C	°F	Method
2-Butoxyethanol		230	446	DIN 51794
3-Butoxypropan-2-ol		260	500	EU A.15
Decomposition temperature	: Not ava	ilable.	-	
рН	: 8 to 8.3	[Conc. (% w/w): 1	00%]	
Viscosity	: Not ava	ilable.		
Solubility(ies)	:			
ate of issue/Date of revision	: 24/10/2023	Date of previous is	sue : 12/10/	/2022 Version : 1.01 9/18
AQUAOIL 2775-36 - All variants				Label No : <mark>5</mark> 2050

SECTION 9: Physical and chemical properties

2

Not available.

Solubility in water	: Not available.
---------------------	------------------

Partition coefficient: n-octanol/ : Not applicable. water

Vapour pressure

	Va	Vapour Pressure at 20°C			Vapour pressure at 50°C			
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method		
water	17.5	2.3						
3-Butoxypropan-2-ol	1.05	0.14	OECD 104					
Relative density	: Not	available.				·		

Density	: 1 g/cm ³
Vapour density	: Not available.
Explosive properties	: Not available.
Oxidising properties	: Not available.
Particle characteristics	
Median particle size	: Not applicable.

SECTION 10: Stability and reactivity			
10.1 Reactivity	: No specific test data related to reactivity available for this product or its ingredients.		
10.2 Chemical stability	: The product is stable.		
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.		
10.4 Conditions to avoid	: No specific data.		
10.5 Incompatible materials	: No specific data.		
10.6 Hazardous decomposition products	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.		

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
3-Butoxypropan-2-ol	LD50 Dermal	Rabbit	3100 mg/kg	-
3-iodo-2-propynyl-butyl carbamate	LC50 Inhalation Dusts and mists	Rat	0.67 g/m³	4 hours
	LC50 Inhalation Dusts and mists	Rat	0.763 mg/l	4 hours
	LD50 Dermal	Rat	>2000 mg/kg	_
	LD50 Oral	Rat	400 mg/kg	-
Cobalt bis(2-ethylhexanoate)	LD50 Dermal	Rabbit	>5 g/kg	-
, , , , , , , , , , , , , , , , , , ,	LD50 Oral	Rat	1.22 g/kg	-
Bronopol	LC50 Inhalation Dusts and mists	Rat	>0.588 mg/l	4 hours
	LD50 Dermal	Rat	4750 mg/kg	-
	LD50 Oral	Rat	307 mg/kg	-
1,2-benzisothiazol-3(2H)- one	LD50 Oral	Rat	1020 mg/kg	-
2-methyl-2H-isothiazol-	LC50 Inhalation Dusts and	Rat	0.11 mg/l	4 hours
e of issue/Date of revision	: 24/10/2023 Date of previous i	ssue : 12/10,	/2022	Version : 1.01 10
UAOIL 2775-36 - All variants			Lal	bel No : <mark>5</mark> 2050

SECTION 11: Toxicolo	ogical information			
3-one 2-Octyl-2H-isothiazol-3-one reaction mass of: 5-chloro- 2-methyl-4-isothiazolin- 3-one [EC no. 247-500-7] and 2-methyl-2H-isothiazol- 3-one [EC no. 220-239-6] (3: 1)	mists LD50 Dermal LD50 Oral LD50 Oral	Rabbit Rat Rat	690 mg/kg 550 mg/kg 53 mg/kg	-

Conclusion/Summary : Based on available data, the classification criteria are not met.

Acute toxicity estimates

Route	ATE value
	83334.32 mg/kg 208.34 mg/l

Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
2-Butoxyethanol	Eyes - Moderate irritant	Rabbit	-	24 hours 100	-
				mg	
	Eyes - Severe irritant	Rabbit	-	100 mg	-
	Skin - Mild irritant	Rabbit	-	500 mg	-
3-Butoxypropan-2-ol	Skin - Moderate irritant	Rabbit	-	-	-
3-iodo-2-propynyl-butyl carbamate	Eyes - Severe irritant	Rabbit	-	-	-
Bronopol	Skin - Mild irritant	Rabbit	-	24 hours 500	-
				mg	
	Skin - Moderate irritant	Human	-	10 mg	-
	Skin - Moderate irritant	Rabbit	-	80 mg	-
1,2-benzisothiazol-3(2H)-one	Skin - Mild irritant	Human	-	48 hours 5 %	-
2-Octyl-2H-isothiazol-3-one	Eyes - Severe irritant	Rabbit	-	100 mg	-
reaction mass of: 5-chloro- 2-methyl-4-isothiazolin-	Skin - Severe irritant	Human	-	0.01 %	-
3-one [EC no. 247-500-7]					
and 2-methyl-2H-isothiazol-					
3-one [EC no. 220-239-6] (3:					
1)					

Conclusion/Summary : Based on available data, the classification criteria are not met.

Sensitisation

Product/ingredient name	Route of exposure	Species	Result
3-iodo-2-propynyl-butyl carbamate	skin	Guinea pig	Not sensitizing

Conclusion/Summary : May cause an allergic skin reaction.

Mutagenicity

Product/ingredient name	Test	Experiment	Result		
3-iodo-2-propynyl-butyl carbamate	-	Experiment: In vitro Subject: Bacteria	Negative		
Conclusion/Summary	: Based on available data, the classification criteria are not met.				
Carcinogenicity Conclusion/Summary <u>Reproductive toxicity</u>	: Based on available data, the classification criteria are not met.				

: 24/10/2023 Date of previous issue

: 12/10/2022

SECTION 11: Toxicological information						
Product/ingredient name	Maternal toxicity	Fertility	Developmental toxin	Species	Dose	Exposure
3-iodo-2-propynyl-butyl carbamate	Negative	-	Negative	Rabbit - Female	Oral: 20 mg/kg	13 days; 7 days per week
	Positive	-	Negative	Rabbit - Female	Oral: 50 mg/kg	13 days; 7 days per week

Conclusion/Summary

: Based on available data, the classification criteria are not met.

Teratogenicity

Product/ingredient name	Result	Species	Dose	Exposure
3-iodo-2-propynyl-butyl carbamate	Negative - Oral	Rabbit - Female	50 mg/kg	-

Conclusion/Summary : Based on available data, the classification criteria are not met.

Specific target organ toxicity (single exposure)

Product/ingredient name	Category	Route of exposure	Target organs
Bronopol	Category 3	-	Respiratory tract irritation

Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
3-iodo-2-propynyl-butyl carbamate	Category 1	-	larynx

Aspiration hazard

Not available.

Information on likely routes of exposure	:	Not available.	
Potential acute health effects	2		
Eye contact	:	No known significant effects or critical hazards.	
Inhalation	:	No known significant effects or critical hazards.	
Skin contact	:	May cause an allergic skin reaction.	
Ingestion	:	No known significant effects or critical hazards.	
Symptoms related to the phy	<u>/sic</u>	al, chemical and toxicological characteristics	
Eye contact	1	No specific data.	
Inhalation	1	No specific data.	
Skin contact	:	Adverse symptoms may include the following: irritation redness	
Ingestion	:	No specific data.	
Delayed and immediate effec	<u>:ts</u>	as well as chronic effects from short and long-term ex	posure
<u>Short term exposure</u>			
Potential immediate effects	1	Not available.	
Potential delayed effects	:	Not available.	
<u>Long term exposure</u>			
Potential immediate effects	:	Not available.	
Potential delayed effects	1	Not available.	
Date of issue/Date of revision		: 24/10/2023 Date of previous issue : 12/10/2022	Version : 1.01 12/18
AQUAOIL 2775-36 - All variant	s		Label No : <mark>5</mark> 2050
L			

SECTION 11: Toxicological information

Potential chronic health effects

Not available.

Conclusion/Summary	: Not available.
General	: Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels.
Carcinogenicity	: No known significant effects or critical hazards.
Mutagenicity	: No known significant effects or critical hazards.
Reproductive toxicity	: No known significant effects or critical hazards.

11.2 Information on other hazards

11.2.1 Endocrine disrupting properties

11.2.2 Other information

Not available.

Not available.

SECTION 12: Ecological information

12.1 Toxicity

Product/ingredient name	Result	Species	Exposure
2-Butoxyethanol	Acute EC50 >1000 mg/l Fresh water	Daphnia - <i>Daphnia magna</i>	48 hours
-	Acute LC50 800000 µg/l Marine water	Crustaceans - Crangon crangon	48 hours
	Acute LC50 1250000 µg/l Marine water	Fish - Menidia beryllina	96 hours
3-iodo-2-propynyl-butyl	Acute EC50 0.022 mg/l Fresh water	Algae - Scenedemus	72 hours
carbamate	C C	subspicatus	
	Acute EC50 0.16 mg/l Fresh water	Daphnia - <i>Daphnia magna</i>	48 hours
	Acute LC50 0.067 mg/l Fresh water	Fish - Oncorhynchus mykiss	96 hours
	Acute NOEC 0.049 mg/l Fresh water	Fish - Oncorhynchus mykiss	96 hours
	Chronic NOEC 0.05 mg/l Fresh water	Daphnia - <i>Daphnia Magna</i>	21 days
Bronopol	Acute EC50 0.4 mg/l	Algae	72 hours
•	Acute EC50 0.02 ppm Fresh water	Algae - Scenedesmus	96 hours
		subspicatus	
	Acute EC50 1.4 mg/l	Daphnia	48 hours
	Acute LC50 41.2 mg/l	Fish	96 hours
	Acute LC50 11.17 ppm Fresh water	Fish - Lepomis macrochirus	96 hours
	Chronic NOEC 1.94 ppm	Fish - Oncorhynchus mykiss	49 days
1,2-benzisothiazol-3(2H)-one	Acute EC50 0.36 mg/l Marine water	Algae - Skeletonema Costatum	72 hours
	Acute EC50 3.7 mg/l	Daphnia - Daphnia Magna	48 hours
	Acute LC50 1.9 mg/l Fresh water	Fish - Onorhynchus Mykiss	96 hours
	Acute NOEC 0.15 mg/l Marine water	Algae - Skeletonema Costatum	72 hours
2-methyl-2H-isothiazol-3-one	Acute EC50 0.18 ppm Fresh water	Daphnia - <i>Daphnia magna</i>	48 hours
,	Acute LC50 0.07 ppm Fresh water	Fish - Oncorhynchus mykiss	96 hours
2-Octyl-2H-isothiazol-3-one	Acute EC50 107 ppb Fresh water	Daphnia - <i>Daphnia magna</i>	48 hours
-	Acute LC50 47 ppb Fresh water	Fish - Oncorhynchus mykiss	96 hours
	Chronic NOEC 74 ppb Fresh water	Daphnia - Daphnia magna	21 days
	Chronic NOEC 8.5 ppb	Fish - Pimephales promelas	35 days

Conclusion/Summary

: Based on available data, the classification criteria are not met.

12.2 Persistence and degradability

Product/ingredient name	Test	Result		Dose	Inoculum
2-benzisothiazol-3(2H)-one	EU	24 % - 28 days		-	-
Conclusion/Summary : This product has not been tested for biodegradation.					
Product/ingredient name	Aquatic half-life		Photolysis	S	Biodegradability
Fiodo-2-propynyl-butyl carbamate Bronopol	-		-		Not readily Readily
1,2-benzisothiazol-3(2H)-one	-		-		Inherent

Date of issue/Date of revision AQUAOIL 2775-36 - All variants : 24/10/2023 Date of previous issue

: 12/10/2022

Version : 1.01 13/18 Label No : 52050

SECTION 12: Ecological information

12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
2-Butoxyethanol	0.81	-	Low
3-Butoxypropan-2-ol	1.2	-	Low
3-iodo-2-propynyl-butyl carbamate	>1	-	Low
Cobalt bis(2-ethylhexanoate)	-	15600	High
Bronopol	0.18	-	Low
1,2-benzisothiazol-3(2H)-one 2-Octyl-2H-isothiazol-3-one	- 2.45	3.2	Low Low

12.4 Mobility in soil	
Soil/water partition coefficient (Koc)	: Not available.
Mobility	: Not available.

12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

12.6 Endocrine disrupting properties

Not available.

12.7 Other adverse effects

No known significant effects or critical hazards.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

io.i waste d'eathent metho	
Product	
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	: The classification of the product may meet the criteria for a hazardous waste.
European waste catalogue (EWC)	: 080112
Packaging	
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.
Special precautions	: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

SECTION 14: Transport information					
	ADR/RID	ADN	IMDG	IATA	
14.1 UN number or ID number	Not regulated.	Not regulated.	Not regulated.	Not regulated.	
14.2 UN proper shipping name	-	-	-	-	
14.3 Transport hazard class(es)	-	-	-	-	
14.4 Packing group	-	-	-	-	
14.5 Environmental hazards	No.	No.	No.	No.	

: Not relevant/applicable due to nature of the product.

user

14.6 Special precautions for : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.

14.7 Maritime transport in bulk according to IMO instruments

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Product/ingredient name		%	Designation [Usage]			
QUAOIL 2775-36		≥90	3			
Labelling	:					
Other EU regulations						
Industrial emissions (integrated pollution prevention and control) - Air	: Not listed					
Industrial emissions (integrated pollution prevention and control) - Water	: Not listed					
Explosive precursors	: Not applicab	le.				
Ozone depleting substance	<u>es (1005/2009/E</u>	<u>U)</u>				
Not listed.						
Prior Informed Consent (P	IC) (649/2012/El	<u>(r</u>				
Not listed.						
Persistent Organic Polluta	nts					
ate of issue/Date of revision	: 24/10/2023	Date of previ	ous issue : 12/10/2022	Version	: 1.01	15/18
QUAOIL 2775-36 - All variant	s			Label No	:5 2050	

SECTION 15: Regulatory information

Not listed.

Seveso Directive

This product is not controlled under the Seveso Directive.

International regulations

Chemical Weapon Convention List Schedules I, II & III Chemicals Not listed.

Montreal Protocol

Not listed.

Stockholm Convention on Persistent Organic Pollutants

Not listed.

Rotterdam Convention on Prior Informed Consent (PIC)

Not listed.

UNECE Aarhus Protocol on POPs and Heavy Metals

Not listed.

15.2 Chemical safety : Not applicable.

assessment

SECTION 16: Other information

Indicates information that has changed from previously issued version.

Abbreviations and acronyms	 ATE = Acute Toxicity Estimate CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008] DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level EUH statement = CLP-specific Hazard statement N/A = Not available PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number
	SGG = Segregation Group vPvB = Very Persistent and Very Bioaccumulative

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification	
Skin Sens. 1, H317	Calculation method	

Full text of abbreviated H statements

⊮ 301	Toxic if swallowed.	
H302	Harmful if swallowed.	
H310	Fatal in contact with skin.	
H311	Toxic in contact with skin.	
H312	Harmful in contact with skin.	
H314	Causes severe skin burns and eye damage.	
H315	Causes skin irritation.	
H317	May cause an allergic skin reaction.	
H318	Causes serious eye damage.	
H319	Causes serious eye irritation.	
H330	Fatal if inhaled.	
H331	Toxic if inhaled.	
H335	May cause respiratory irritation.	
H360FD	May damage fertility. May damage the unborn child.	
H372	Causes damage to organs through prolonged or repeated exposure.	
H400	Very toxic to aquatic life.	
H410	Very toxic to aquatic life with long lasting effects.	
Date of issue/Dat	te of revision : 24/10/2023 Date of previous issue : 12/10/2022	Version : 1.01 16/18
AQUAOIL 277	5-36 - All variants	Label No :52050

SECTION 16: Other information	
H412 Har	ic to aquatic life with long lasting effects. mful to aquatic life with long lasting effects. rosive to the respiratory tract.
Full text of classifications [CLP/GHS]	
Acute Tox. 2 Acute Tox. 3 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 Aquatic Chronic 2 Aquatic Chronic 3 Eye Dam. 1 Eye Irrit. 2 Repr. 1B Skin Corr. 1 Skin Corr. 1 Skin Corr. 1C Skin Irrit. 2 Skin Sens. 1 Skin Sens. 1 SKIN SENS. 1A STOT RE 1 STOT SE 3	ACUTE TOXICITY - Category 2 ACUTE TOXICITY - Category 3 ACUTE TOXICITY - Category 4 SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2 LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 3 SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1 SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2 REPRODUCTIVE TOXICITY - Category 1B SKIN CORROSION/IRRITATION - Category 1 SKIN CORROSION/IRRITATION - Category 1C SKIN CORROSION/IRRITATION - Category 2 SKIN SENSITISATION - Category 1 SKIN SENSITISATION - CATEGORY 1 SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 1 SPECIFIC TARGET ORGAN TOXICITY - SINGLE EXPOSURE - Category 3
Date of issue/ Date o	f : 24/10/2023
revision Date of previous issu	Je : 12/10/2022
Version	: 1.01

Notice to reader

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

Date of issue/Date of revision AQUAOIL 2775-36 - All variants : 24/10/2023 Date of previous issue